Multicenter phase II study of combination therapy with cetuximab and S-1 in patients with KRAS exon 2 wild-type unresectable colorectal cancer previously treated with irinotecan, oxaliplatin, and fluoropyrimidines (KSCC 0901 study)
Crossref DOI link: https://doi.org/10.1007/s00280-016-3109-4
Published Online: 2016-07-28
Published Print: 2016-09
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Takahashi, Takao
,
Emi, Yasunori
Oki, Eiji
Kobayashi, Kazuma
Tsuji, Akihito
Shimokawa, Mototsugu
Tanaka, Takaho
Akagi, Yoshito
Ogata, Yutaka
Baba, Hideo
Yoshida, Kazuhiro
Natsugoe, Shoji
Maehara, Yoshihiko
License valid from 2016-07-28